Literature DB >> 7839730

Effects of cholera toxin adjuvant on IgE antibody response to orally or nasally administered ovalbumin.

S Tamura1, Y Shoji, K Hasiguchi, C Aizawa, T Kurata.   

Abstract

Effects of cholera toxin B subunits supplemented with 0.1% cholera toxin (CTB*) on systemic IgE antibody responses to ovalbumin (OVA) were examined in BDFI (H-2b/d), Balb/c (H-2d) and C3H (H-2k) mice given OVA intragastrically or intranasally. Two successive doses of OVA intragastrically administered to Balb/c and C3H mice induced little IgE response and resulted in almost complete unresponsiveness to subsequent intraperitoneal challenge with OVA in Al(OH)3, while the intragastric administration to BDF1 mice induced high IgE response and resulted in abrogation of the unresponsiveness to the subsequent challenge. The intranasal administration of OVA induced little IgE response and suppressed response to the subsequent challenge in any strain of mice. On the other hand, two successive doses of intragastric or intranasal OVA together with CTB* enhanced IgE response in all three strains and the subsequent challenge with OVA in Al(OH)3 induced higher IgE responses. These results suggest that CTB* augments IgE response to OVA and abrogates the unresponsiveness when administered orally or intranasally into mice together with OVA, regardless of the H-2 haplotype of the mice.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7839730     DOI: 10.1016/0264-410x(94)90250-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection.

Authors:  N Debard; D Buzoni-Gatel; D Bout
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

2.  Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina.

Authors:  C Bergquist; E L Johansson; T Lagergård; J Holmgren; A Rudin
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

3.  Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunit.

Authors:  M W Russell; Z Moldoveanu; P L White; G J Sibert; J Mestecky; M Michalek S
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

4.  Effects of adjuvants on the immune response to allergens in a murine model of allergen inhalation: cholera toxin induces a Th1-like response to Bet v 1, the major birch pollen allergen.

Authors:  U Wiedermann; B Jahn-Schmid; R Fritsch; L Bauer; H Renz; D Kraft; C Ebner
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

5.  Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.

Authors:  Pallavi R Manuri; Bharti Nehete; Pramod N Nehete; Rose Reisenauer; Seth Wardell; Amy N Courtney; Ratish Gambhira; Dakshyani Lomada; Ashok K Chopra; K Jagannadha Sastry
Journal:  Vaccine       Date:  2007-01-24       Impact factor: 3.641

6.  A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins.

Authors:  M Roberts; A Bacon; R Rappuoli; M Pizza; I Cropley; G Douce; G Dougan; M Marinaro; J McGhee; S Chatfield
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

7.  Recombinant antigen-enterotoxin A2/B chimeric mucosal immunogens differentially enhance antibody responses and B7-dependent costimulation of CD4(+) T cells.

Authors:  M Martin; G Hajishengallis; D J Metzger; S M Michalek; T D Connell; M W Russell
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

8.  Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression.

Authors:  M C Braun; J He; C Y Wu; B L Kelsall
Journal:  J Exp Med       Date:  1999-02-01       Impact factor: 14.307

9.  Intranasal influenza vaccination using a new synthetic mucosal adjuvant SF-10: induction of potent local and systemic immunity with balanced Th1 and Th2 responses.

Authors:  Takashi Kimoto; Dai Mizuno; Tsunetomo Takei; Takuya Kunimi; Shinji Ono; Satoko Sakai; Hiroshi Kido
Journal:  Influenza Other Respir Viruses       Date:  2013-05-26       Impact factor: 4.380

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.